Pediatric
Migraine
Study
Pediatric Migraine Clinical Trial
Biohaven Pharmaceuticals is studying an investigational drug, called rimegepant, for the acute treatment of migraines in the pediatric population. If your child is between 12 and 17 years of age and has at least a 6-month history of migraine, they may qualify. The investigational drug, plus all study-related assessments, will be provided at no cost to you.
Health insurance is not required to take part in this study and compensation for participation may also be provided.
Who is this study for?
Teens may qualify for this study if they meet the following criteria:
Between the ages of 12 and 17
Have at least 1 migraine per month
Have at least a 6-month history of migraine
The migraine study clinicians will further assess medical and migraine history to determine eligibility.
By the time they turn 17, as many as 8% of boys and 23% of girls have experienced a migraine.
What is This Pediatric Migraine Clinical Trial All About?
This is a research study, or clinical trial, to test a medication approved by the FDA for the treatment of acute migraine and prevention of episodic migraine in adults. The purpose of this study is to learn how well the study drug works and how safe the study drug is to treat migraine in children and teens compared to placebo. The investigational drug, plus all study-related assessments, will be provided at no cost to you.
Health insurance is not required to take part in this study and compensation for participation may also be provided.
What is a Migraine?
Migraine is a chronic and debilitating disorder that affects approximately 15% of the adult population. In young children, usually those below the age of 15 years, migraine headaches may be bi-lateral or unilateral, and may be non-throbbing. The patient may look ill and pale, may feel dizzy, have blurred vision, and fever. Nausea and vomiting are frequent, particularly in young children (defined as 7 years of age). Patients tend to avoid light (photophobia), noise (phonophobia), strong odors, and movement.
What is the Investigational Drug?
The investigational drug being evaluated is called rimegepant. It has already been approved by the FDA and is currently being prescribed by doctors for the treatment of migraine in adults.
Who Can Participate in the Trial?
Children and teens who are 12 through 17 years old and have had 1 to 8 migraines per month for the last 2 months may qualify. The clinical trial staff will further assess medical and migraine history to determine eligibility.
Biohaven is a commercial stage biopharmaceutical company with innovative drug candidates targeting neurological diseases. Learn more about Biohaven Pharmaceuticals.
©2024 by Biohaven Pharmaceuticals